Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

n circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its products or product candidates;

-- the Company's ability to enter into and successfully execute license and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the Company's risk of bankruptcy if it is unsuccessful in obtaining such financing or in securing shareholder approval to increase the number of shares authorized for issuance under the Company's certificate of incorporation, as required by the transactional documents in our recent financing;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and any proposed settlement of such litigation; and

-- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Inves
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... created a deicing film for radar domes have now ... for glass. , The new work by Rice ... surfaces from windshields to skyscrapers free of ice and ... , The technology was introduced this month in ... Interfaces . , The material is made of ...
(Date:9/16/2014)... Fresne, President and CEO of Egenix, Inc. is pleased to ... its Scientific Advisory Committee. Dr. Vagner, a graduate ... performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... of health and medical research. He is a Research Director ... France , and at the Gustave Roussy ...
(Date:9/16/2014)... Sept. 16, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... the completion of the Company,s Investor Day in ... its irritable bowel syndrome (IBS) program, including its ... In the keynote presentation, Mark ...
Breaking Biology Technology:Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will,be ... Tuesday, August 5th at 11:30 am Eastern Time., Event: ... Dan Starck, President and CEO ... 11:30 am Eastern Time, Tuesday, August ...
... Researchers at Fred Hutchinson Cancer,Research Center have received ... Genome Research Institute to better understand the genetic,and ... is one of,four U.S. research institutes to receive ... The Hutchinson Center project, led by biostatistician and ...
... MOUNTAINSIDE, N.J., July 17 National Stem,Cell Holding, ... owned,subsidiary Proteoderm, Inc. is exhibiting at the 16th ... in Washington, DC on July,17 -- 19, 2008. ... speak as a,scientific keynote panelist. Dr. Steiner will ...
Cached Biology Technology:CorVel Corporation Announces Earnings Release Webcast 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 3National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine 2
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
(Date:9/15/2014)... for both plants and animals alike. , Understanding just ... lead to the design of better drugs for diabetes ... and vegetables farmers are able to grow. Stanford University ... the cell by piecing together proteins slightly wider than ... To determine the size, shape and orientation of one ...
(Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2
... Each year, millions of monarch butterflies ( Danaus ... to colonize eastern North America, but just how these ... their breeding range in spring has largely remained a ... Guelph led by Prof. Ryan Norris, Department of Integrative ...
... musculus ) happily live wherever there are humans. When ... them. New research published in BioMed Central,s open access ... techniques on modern day and ancestral mouse mitochondrial DNA ... that of Viking invasion. During the Viking age ...
... Calif., March 18, 2012 Autoimmune diseases, such as ... an immune system gone haywire, where the body,s defense ... of a protein called LYP has been implicated in ... has been unknown. Now, in a paper published March ...
Cached Biology News:Study reveals how monarch butterflies recolonize northern breeding range 2The Viking journey of mice and men 2New insight into mechanisms behind autoimmune diseases suggests a potential therapy 2
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
... hydrophobic barrier pen for immunohistochemistry and in ... frozen or paraffin-embedded tissue sections mounted on ... heat-stable, water-repellent barrier that keeps staining reagents ... of reagents when differentially staining two sections ...
Biology Products: